RECURSION PHARMACEUTICALS, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $22.08 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $0.00.
- RECURSION PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-12-31 was $0.00.
- RECURSION PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $22.08M.
- RECURSION PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $0.00.
- RECURSION PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $22.08M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $22.08M 10-Q · filed 2025-11-05 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |